modelElectrolytesInCombinatio
Extends from Pharmacolibrary.Drugs.ATC.B.B05CB10.
Information
| name: | ElectrolytesInCombination | |
| ATC code: | B05CB10 | route: | intravenous |
| compartments: | 0 | |
| dosage: | 500 | mg |
| volume of distribution: | 1 | L |
| clearance: | 0 | |
| other parameters in model implementation | ||
This preparation contains combinations of electrolytes such as sodium, potassium, calcium, and magnesium, typically used for intravenous infusion to correct or prevent disturbances in electrolyte and fluid balance, especially in clinical situations such as dehydration, surgery, or intensive care. ATC code B05CB10 specifically refers to solutions containing combinations of electrolytes. These combinations are still widely used and are considered standard supportive therapy in modern medicine.
Pharmacokinetics
No pharmacokinetic parameters specific to electrolyte solutions (combinations) for B05CB10 could be found in the literature, as electrolytes do not follow traditional pharmacokinetic models used for most drugs. Electrolyte kinetics depend on physiological and pathophysiological processes rather than standard compartmental PK models.
References
Bateman, RM, et al., & Prandi, E (2016). 36th International Symposium on Intensive Care and Emergency Medicine : Brussels, Belgium. 15-18 March 2016. Critical care (London, England) 20(Suppl 2) 94–None. DOI:10.1186/s13054-016-1208-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27885969
Levitskaia, TG, et al., & Thrall, KD (2010). Biomaterials for the decorporation of (85)Sr in the rat. Health physics 99(3) 394–400. DOI:10.1097/HP.0b013e3181c4717d PUBMED:https://pubmed.ncbi.nlm.nih.gov/20699703
Yang, S, et al., & Peachey, G (2021). Population Pharmacokinetic Modeling of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol in Patients with Asthma, Using Data from a Phase IIIA Study (CAPTAIN). Clinical pharmacokinetics 60(7) 887–896. DOI:10.1007/s40262-021-00988-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33598874
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)